Immunosuppressive therapy is generally safe for pediatric-onset inflammatory bowel disease (IBD), according to preliminary findings from a European study.
Immunosuppression has been linked to an increased risk for cancer in patients with early-onset IBD. However, whether the risk results from the treatment or the disease itself—such as colon adenocarcinomas arising from chronic inflammation—is unclear, said Linda Joosse, MD, a PhD student in the Department of Pediatric